Paper Details

  1. Home
  2. Paper Details

Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior.

Author: Al QtaishNuseibah, CaruanaPablo, CorcoyRosa, CéspedesMaría Virtudes, EdwardsMaria, Escolà-GilJuan Carlos, GallegoIdoia, LiChangda, Lopez-MendezTania, MatoEugènia, MoralAntonio, Paez-EspinosaVerónica, PedrazJosé Luis, PurasGustavo, PérezJosé Ignacio, RevillaGiovanna, RodriguezFrancisco, Sainz-RamosMyriam, VallverdúNúria Fucui

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Lenvatinib is a tyrosine kinase inhibitor used to treat thyroid cancer, but it can cause significant side effects. This study investigated the use of lenvatinib-loaded PLGA nanoparticles to improve drug delivery and reduce side effects. The nanoparticles were effective in reducing tumor growth in vitro and in vivo. Using antibodies to target the nanoparticles to specific tumor cells may further enhance efficacy and minimize side effects.
Paper Details　
Original Abstract of the Article :
Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects that can be partially mitigated through the development of novel drug formulations. The ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668968/

データ提供：米国国立医学図書館（NLM）

Lenvatinib-Loaded Nanoparticles: A Desert Oasis for Thyroid Cancer Treatment

In the fight against [aggressive thyroid cancer], researchers are constantly seeking innovative therapeutic approaches. This research explores the potential of [lenvatinib-loaded poly(lactic-co-glycolic acid) nanoparticles (NPs)] as a novel treatment strategy. The authors investigated the [cytotoxicity, biodistribution, and therapeutic efficacy] of these NPs, both with and without antibody conjugation. Their preclinical studies suggest that these NPs could [effectively target and kill thyroid cancer cells] while minimizing side effects. This research presents a promising avenue for [improving the treatment of aggressive thyroid tumors] and enhancing the quality of life for patients.

Navigating the Sands of Thyroid Cancer Treatment

The results of this study offer hope for patients with aggressive thyroid cancer. It's like finding a hidden oasis in the vast desert of cancer treatment. The use of [lenvatinib-loaded NPs] presents a novel approach that could [revolutionize the treatment of thyroid cancer]. Imagine a world where patients can receive [targeted and effective treatment] without the burden of debilitating side effects.

A Glimpse into the Future of Thyroid Cancer Treatment

This research signifies a significant step forward in the fight against thyroid cancer. Just as a desert traveler relies on their knowledge of the terrain, researchers are constantly exploring new frontiers in cancer treatment. This study highlights the potential of [nanotechnology] to revolutionize the way we approach cancer therapy.

Dr. Camel's Conclusion

This study provides exciting evidence for the potential of lenvatinib-loaded NPs as a novel therapeutic strategy for aggressive thyroid cancer. The research highlights the importance of innovation in developing targeted and effective treatments that improve patient outcomes and enhance their quality of life. It's like finding a source of fresh water in the desert, offering hope and a brighter future for patients battling this challenging disease.

Date :
  1. Date Completed 2023-11-27
  2. Date Revised 2023-11-27
Further Info :

Pubmed ID

38002329

DOI: Digital Object Identifier

PMC10668968

Related Literature

Article Analysis
・Side Effects of lenvatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.